Determinants of managed entry agreements in the context of health technology assessment: a comparative analysis of oncology therapies in four countries

29 January 2021 - Managed entry agreements are increasingly used to address uncertainties arising in the health technology assessment process due ...

Read more →

Evaluation of the impact of patient input in health technology assessments at NICE

29 January 2021 - Accounts of patient experiences are increasingly used in health technology assessment processes. However, we know little about ...

Read more →

On the role of cost effectiveness thresholds in health care priority setting

25 January 2021 - In the past few years, empirical estimates of the marginal cost at which health care produces a ...

Read more →

Creating a patient and community advisory committee at the Canadian Agency for Drugs and Technologies in Health

22 January 2021 - In recognition of patients’ roles using, and contributing to, a publicly funded health system, the Canadian Agency ...

Read more →

STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies

12 January 2021 - In alignment with the International Council of Harmonization’s strategic goals, a public private consortium has developed a ...

Read more →

Evaluating New Zealanders’ values for drug coverage decision-making: trade-offs between treatments for rare and common conditions

8 January 2021 - The objectives of this study were to measure the relative societal importance of values of New Zealanders ...

Read more →

Shared decision making is an integral part of healthcare, says NICE

22 December 2020 - Shared decision making between patients and clinicians should be embedded throughout healthcare services, says NICE, in draft ...

Read more →

Update on funding decision for two new diabetes medicines

7 December 2020 - PHARMAC would like to thank everyone who has provided feedback to date on a proposal to ...

Read more →

Government promises independent PHARMAC review after Labour MPs veto Health Select Committee inquiry

3 December 2020 - National MPs have lashed out at Labour for voting against a politician-led inquiry into PHARMAC but ...

Read more →

ICER opens nominations for new members of its voting panels

2 December 2020 - Independent panel members debate the evidence on the effectiveness and value of new drugs and other ...

Read more →

PHARMAC inquiry: “nothing should be off the table”

4 December 2020 - Medicines New Zealand, the industry association representing companies involved in the research, development and manufacture of ...

Read more →

Fate of 250,000 diabetics in PHARMAC’s hands

3 December 2020 - This week, a small group of bureaucrats and health professionals will meet to agree on the ...

Read more →

PHARMAC won’t release the data that changed its mind on diabetes

13 November 2020 - Diabetes Foundation Aotearoa will request the Ombudsman investigate the refusal by PHARMAC to release public submissions ...

Read more →

Expertise, experience, and excellence. Twenty years of patient involvement in health technology assessment at NICE: an evolving story

10 November 2020 - From its inception in 1999, NICE committed to including the expertise, experiences, and perspectives of lay people, ...

Read more →

A health opportunity cost threshold for cost effectiveness analysis in the United State

3 November 2020 - Cost effectiveness analysis is an important tool for informing treatment coverage and pricing decisions, yet no consensus ...

Read more →